CytomX Therapeutics, Inc. (CTMX) financial statements (2022 and earlier)

Company profile

Business Address 151 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:266,349236,289266,177346,248256,298296,133296,140
Cash and cash equivalents205,530236,284256,146329,666191,859176,810291,388
Short-term investments99,696510,03164,130124,260144,26655,013
Other undisclosed cash, cash equivalents, and short-term investments(38,877)  (47,548)(59,821)(24,943)(50,261)
Receivables79088793175679813,60413,267
Other undisclosed current assets43,1623,8223,89753,00466,91730,56857,159
Total current assets:310,301240,998271,005400,008324,013340,305366,566
Noncurrent Assets
Operating lease, right-of-use asset19,36220,17020,96121,73622,49523,23923,967
Property, plant and equipment5,9606,2716,6997,1726,9507,1907,461
Long-term investments and receivables 99,96999,914    
Long-term investments 99,96999,914    
Intangible assets, net (including goodwill)1,9702,0062,0432,0792,1162,1522,189
Goodwill949949949949949949949
Intangible assets, net (excluding goodwill)1,0211,0571,0941,1301,1671,2031,240
Restricted cash and investments917917917917917917917
Other noncurrent assets9019029012,2462,1721,3791,379
Total noncurrent assets:29,110130,235131,43534,15034,65034,87735,913
TOTAL ASSETS:339,411371,233402,440434,158358,663375,182402,479
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities37,05426,68321,00821,41326,05527,58826,074
Accounts payable2,8181,5161,7552,5822,9963,6434,927
Accrued liabilities34,23625,16719,25318,83123,05923,94521,147
Deferred revenue69,26273,08972,36976,63674,86974,44572,711
Total current liabilities:106,31699,77293,37798,049100,924102,03398,785
Noncurrent Liabilities
Long-term debt and lease obligation18,05619,01719,92120,80721,67522,52523,323
Operating lease, liability18,05619,01719,92120,80721,67522,52523,323
Liabilities, other than long-term debt125,660140,770158,189169,280186,261202,560221,542
Deferred revenue125,660140,770158,189169,280186,261202,560221,542
Total noncurrent liabilities:143,716159,787178,110190,087207,936225,085244,865
Total liabilities:250,032259,559271,487288,136308,860327,118343,650
Stockholders' equity
Stockholders' equity attributable to parent89,379111,674130,953146,02249,80348,06458,829
Common stock1111111
Additional paid in capital623,344619,117615,849611,733499,964483,524479,516
Accumulated other comprehensive income (loss)(242)5215(43)(47)(47)16
Accumulated deficit(533,724)(507,496)(484,912)(465,669)(450,115)(435,414)(420,704)
Total stockholders' equity:89,379111,674130,953146,02249,80348,06458,829
TOTAL LIABILITIES AND EQUITY:339,411371,233402,440434,158358,663375,182402,479

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues19,72717,58716,28815,97116,37317,78816,608
Gross profit:19,72717,58716,28815,97116,37317,78816,608
Operating expenses(46,035)(40,228)(35,493)(31,598)(31,152)(32,683)(32,746)
Operating loss:(26,308)(22,641)(19,205)(15,627)(14,779)(14,895)(16,138)
Nonoperating income (expense)8057(38)7378185459
Investment income, nonoperating73704468106200454
Other nonoperating income (expense)7(13)(82)5(28)(15)5
Net loss available to common stockholders, diluted:(26,228)(22,584)(19,243)(15,554)(14,701)(14,710)(15,679)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(26,228)(22,584)(19,243)(15,554)(14,701)(14,710)(15,679)
Comprehensive loss:(26,228)(22,584)(19,243)(15,554)(14,701)(14,710)(15,679)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(294)37584 (63)(320)
Comprehensive loss, net of tax, attributable to parent:(26,522)(22,547)(19,185)(15,550)(14,701)(14,773)(15,999)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: